Concord Biotech Limited announced its unaudited consolidated financial results for the first quarter ended June 30, 2026. The Board of Directors, following a review by the Audit Committee, approved the standalone and consolidated financial statements. The results reflect the company’s performance during the initial quarter of the fiscal year.
Concord Biotech Approves Q1 FY27 Financial Results
Concord Biotech Limited has announced the outcome of its Board meeting held on July 31, 2026. During this meeting, the Board of Directors, upon the recommendation of the Audit Committee, considered and approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026.
Key Financial Information
The financial statements, which have undergone a limited review by statutory auditors M/s. BSR & Co. LLP, were presented and approved. The unaudited financial results for the quarter ended June 30, 2026, along with the accompanying Limited Review Report, have been disseminated as per regulatory requirements.
The Board meeting commenced at 03:30 P.M. and concluded at 4:35 P.M. on the aforementioned date.
Consolidated Financial Highlights (Quarter Ended June 30, 2026)
Key figures from the consolidated results include:
- Revenue from operations: ₹25,748.90 lakhs
- Profit after tax: ₹5,769.69 lakhs
- Total comprehensive income: ₹7,475.83 lakhs
Standalone Financial Highlights (Quarter Ended June 30, 2026)
Key figures from the standalone results include:
- Revenue from operations: ₹26,051.71 lakhs
- Profit after tax: ₹6,119.37 lakhs
- Total comprehensive income: ₹7,824.64 lakhs
Source: BSE
